Accelerate Diagnostics Stock Buy Hold or Sell Recommendation
| AXDX Stock | USD 1.64 0.03 1.80% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Accelerate Diagnostics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Accelerate Diagnostics given historical horizon and risk tolerance towards Accelerate Diagnostics. When Macroaxis issues a 'buy' or 'sell' recommendation for Accelerate Diagnostics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Accelerate Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide. In addition, we conduct extensive research on individual companies such as Accelerate and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Accelerate |
Execute Accelerate Diagnostics Buy or Sell Advice
The Accelerate recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Accelerate Diagnostics. Macroaxis does not own or have any residual interests in Accelerate Diagnostics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Accelerate Diagnostics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Accelerate Diagnostics Trading Alerts and Improvement Suggestions
| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics may become a speculative penny stock | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Earnings call Accelerate Diagnostics Q3 results and FDA clearances |
Accelerate Diagnostics Returns Distribution Density
The distribution of Accelerate Diagnostics' historical returns is an attempt to chart the uncertainty of Accelerate Diagnostics' future price movements. The chart of the probability distribution of Accelerate Diagnostics daily returns describes the distribution of returns around its average expected value. We use Accelerate Diagnostics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Accelerate Diagnostics returns is essential to provide solid investment advice for Accelerate Diagnostics.
| Mean Return | 0.01 | Value At Risk | -7.11 | Potential Upside | 8.02 | Standard Deviation | 4.06 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Accelerate Diagnostics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Accelerate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Accelerate Diagnostics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Accelerate Diagnostics back and forth among themselves.
| Shares | State Street Corp | 2024-06-30 | 20.4 K | Ironwood Wealth Management, Llc | 2024-09-30 | 20.3 K | Y-intercept (hong Kong) Ltd | 2024-09-30 | 19.9 K | Millennium Management Llc | 2024-06-30 | 19.6 K | Tudor Investment Corp Et Al | 2024-09-30 | 14.1 K | Tejara Capital Ltd | 2024-06-30 | 13.6 K | Group One Trading, Lp | 2024-06-30 | 13.4 K | Citadel Advisors Llc | 2024-09-30 | 12.5 K | Occudo Quantitative Strategies Lp | 2024-09-30 | 11.2 K | Armistice Capital, Llc | 2024-09-30 | 2.1 M | Hovey Youngman Associates Inc | 2024-09-30 | 1.2 M |
Accelerate Diagnostics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (5.2M) | (25.2M) | 4.1M | (5.0M) | (22.8M) | (21.6M) | |
| Free Cash Flow | (65.1M) | (51.8M) | (47.9M) | (49.3M) | (41.2M) | (39.2M) | |
| Depreciation | 2.6M | 3.0M | 2.5M | 3M | 3.3M | 3.4M | |
| Other Non Cash Items | 10.0M | 11.2M | 11.5M | (2.1M) | 7.8M | 8.2M | |
| Capital Expenditures | 330K | 1.4M | 603K | 554K | 1.0M | 717.4K | |
| Net Income | (84.3M) | (78.2M) | (77.7M) | (62.5M) | (61.6M) | (58.5M) | |
| End Period Cash Flow | 61.0M | 35.8M | 39.9M | 34.9M | 12.1M | 23.7M | |
| Change To Inventory | (3.7M) | (1.4M) | (415K) | (236K) | 446K | 468.3K | |
| Change Receivables | 86K | (1.4M) | 1.6M | (770K) | (693K) | (658.4K) | |
| Change To Netincome | 13.4M | 17.6M | 16.4M | 7.2M | 8.3M | 11.6M | |
| Investments | 53.1M | 15.0M | 8.9M | 12.4M | 14.6M | 15.3M |
Accelerate Diagnostics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Accelerate Diagnostics or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Accelerate Diagnostics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Accelerate stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | -0.58 | |
σ | Overall volatility | 4.08 | |
Ir | Information ratio | -0.03 |
Accelerate Diagnostics Volatility Alert
Accelerate Diagnostics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Accelerate Diagnostics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Accelerate Diagnostics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Accelerate Diagnostics Fundamentals Vs Peers
Comparing Accelerate Diagnostics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Accelerate Diagnostics' direct or indirect competition across all of the common fundamentals between Accelerate Diagnostics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Accelerate Diagnostics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Accelerate Diagnostics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Accelerate Diagnostics to competition |
| Fundamentals | Accelerate Diagnostics | Peer Average |
| Return On Asset | -0.76 | -0.14 |
| Operating Margin | (2.88) % | (5.51) % |
| Current Valuation | 79.13 M | 16.62 B |
| Shares Outstanding | 25.04 M | 571.82 M |
| Shares Owned By Insiders | 40.60 % | 10.09 % |
| Shares Owned By Institutions | 17.45 % | 39.21 % |
| Number Of Shares Shorted | 510.51 K | 4.71 M |
| Price To Earning | (15.18) X | 28.72 X |
| Price To Sales | 3.36 X | 11.42 X |
| Revenue | 12.06 M | 9.43 B |
| Gross Profit | 3.3 M | 27.38 B |
| EBITDA | (49.77 M) | 3.9 B |
| Net Income | (61.62 M) | 570.98 M |
| Cash And Equivalents | 36.77 M | 2.7 B |
| Cash Per Share | 0.45 X | 5.01 X |
| Total Debt | 39.22 M | 5.32 B |
| Debt To Equity | 2.76 % | 48.70 % |
| Current Ratio | 4.48 X | 2.16 X |
| Book Value Per Share | (1.36) X | 1.93 K |
| Cash Flow From Operations | (40.2 M) | 971.22 M |
| Short Ratio | 7.77 X | 4.00 X |
| Earnings Per Share | (2.59) X | 3.12 X |
| Price To Earnings To Growth | (0.55) X | 4.89 X |
| Target Price | 1.5 | |
| Number Of Employees | 134 | 18.84 K |
| Beta | 0.6 | -0.15 |
| Market Capitalization | 41.07 M | 19.03 B |
| Total Asset | 31.37 M | 29.47 B |
| Retained Earnings | (668.86 M) | 9.33 B |
| Working Capital | 12.43 M | 1.48 B |
| Current Asset | 91.68 M | 9.34 B |
| Current Liabilities | 4.45 M | 7.9 B |
| Net Asset | 31.37 M |
Note: Disposition of 4737 shares by Regan Jennifer of Accelerate Diagnostics subject to Rule 16b-3 [view details]
Accelerate Diagnostics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Accelerate . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Accelerate Diagnostics Buy or Sell Advice
When is the right time to buy or sell Accelerate Diagnostics? Buying financial instruments such as Accelerate Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Accelerate Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.